Importantly, Fc-TRAIL showed higher potency in inducing apoptosis in cancer cells in vitro and in vivo without exerting hepatotoxicity.115 Furthermore, a compound in which two trimers of the extracellular domain of TRAIL are fused to an Fc-part of human IgG1 generating a hexavalent TRA has recently been developed (APG350).116 APG350 demonstrated potent apoptosis induction in cancer cell lines, primary cancer cells and in xenograft mouse models. The gene discussed is TNFSF10; the disease is cancer.